A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.

By recreating a fetal liver niche, FLOs show how liver and immune cells co-develop. Learn more about new groundbreaking ...

The study reveals that nicotinic acid (vitamin B3) significantly protects the liver during ischemia-reperfusion injury by ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

Dry January is here and many people will be taking the opportunity to reset their health at the start of the year, and who ...

King Faisal Specialist Hospital & Research Centre continues to advance pediatric care through specialized programs dedicated to solid tumors and non-malignant blood disorders, supported by ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor ...

Going by his words, understanding the human brain is far more complex than comprehending the entire solar system. Veteran ...